Proposed flat reimbursement rates for Medicare Advantage are expected to reduce CVS Health's enrollment due to higher premiums through FY2027. Despite this challenge, CVS's diversified healthcare segments and a potentially healthier membership base at higher rates should support sustainable operations. The stock is currently undervalued with a forward P/E of 9.97x and a 3-year PEG of 0.85x, offering a dividend yield of 3.72%, which is attractive compared to peers and historical averages. Investors willing to endure a slow recovery may benefit from compelling dividends and eventual capital appreciation.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
